Tg Therapeutics Stock News

Investors are rattled by the FDA's request for an out-of-the-ordinary meeting dedicated to scrutinizing the company's latest drug approval request.

Company to host conference call today, Tuesday, November 30, 2021 at 8:30 AM ET Company to host conference call today, Tuesday, November 30, 2021 at 8:30 AM ET

TG Therapeutics Inc (NASDAQ: TGTX) is trading lower Tuesday after the company reported the U.S. Food and Drug Administration plans to host a meeting of the Oncologic Drugs Advisory Committee in conn

TG Therapeutics Inc (NASDAQ:TGTX) stock is plummeting today, down 45.4% to trade at $12.75 at last check.

Wall Street brokerages expect that TG Therapeutics, Inc. (NASDAQ:TGTX) will report ($0.62) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Four analysts have provided estimates for TG Therapeutics earnings, with the lowest EPS estimate coming in at ($0.74) and the highest estimate coming in at ($0.45). TG Therapeutics reported earnings []

TG Therapeutics Inc. (NASDAQ:TGTX) shares, rose in value on Friday, 11/26/21, with the stock price down by -5.63% to the previous days close as strong demand from buyers drove the stock to $23.98. Actively observing the price movement in the last trading, the stock closed the session at $25.41, falling within a range of $23.69 Before You Sell TG Therapeutics Inc. (NASDAQ: TGTX) Shares, HeresWhat You Need To Know. Read More »

Millennium Management LLC cut its holdings in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) by 62.3% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 119,214 shares of the biopharmaceutical company’s stock after selling 197,257 shares during the period. Millennium Management LLC’s holdings in TG Therapeutics were […]

Invesco Ltd. lifted its position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) by 1.9% during the 2nd quarter, HoldingsChannel.com reports. The fund owned 1,121,293 shares of the biopharmaceutical companys stock after acquiring an additional 20,398 shares during the quarter. Invesco Ltd.s holdings in TG Therapeutics were worth $43,496,000 as of its most recent filing with []

Related Stocks: TGTX , ISEE , RNW , ATRA , IMRA , MCRB , ORGN , CNP , EXTR , CSIQ ,

A new call from a well-known Wall Street firms casts a fresh shadow of doubt on the drugmaker's actual revenue prospects.

Fireside chat available for on demand download at 5:00 PM GMT/ 3:00 AM ET on Thursday November 18, 2021 Fireside chat available for on demand download at 5:00 PM GMT/ 3:00 AM ET on Thursday November 18, 2021

TG Therapeutics, Inc. (NASDAQ:TGTX) Equities researchers at Cantor Fitzgerald decreased their FY2021 earnings per share estimates for shares of TG Therapeutics in a research note issued to investors on Wednesday, November 10th. Cantor Fitzgerald analyst A. Young now anticipates that the biopharmaceutical company will post earnings per share of ($2.61) for the year, down []

Amalgamated Bank grew its holdings in TG Therapeutics, Inc. (NASDAQ:TGTX) by 49.2% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 24,206 shares of the biopharmaceutical companys stock after purchasing an additional 7,982 shares during the quarter. Amalgamated Banks holdings in TG Therapeutics were worth []

TG Therapeutics, Inc. (TGTX) CEO Mike Weiss on Q3 2021 Results - Earnings Call Transcript